Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer
A Randomised Trial in Relapsed Ovarian Cancer: Early Treatment Based on CA 125 Levels Alone Vs. Delayed Treatment Based On Conventional Clinical Indicators
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
This PHASE3 trial investigates Fallopian Tube Cancer and Ovarian Cancer and is currently completed. European Organisation for Research and Treatment of Cancer - EORTC leads this study, which shows 6 recorded versions since 1996 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jun 1996
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Organisation for Research and Treatment of Cancer - EORTC
- Medical Research Council
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands, Barcelona, Spain, Brescia, Italy, Brussels, Belgium, Caen, France, Cape Town, South Africa, Coimbra, Portugal, Dublin, Ireland, Kortrijk, Belgium, Leiden, Netherlands and 8 more location s